Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

Day 1 :
WEDNESDAY, 2 SEPTEMBER, 2026
08:30 - 09:30
REGISTRATION AND MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:10
RESERVED PRESENTATION
10:10 - 10:40
SPEED NETWORKING SESSION
  • Exchange business cards and get connected in short one-to-one meetings
  • Start the conversation to arrange a more formal meeting later on in the conference
  • Share your professional background and discuss your biggest business issues - don't forget your business cards!
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON EUROPEAN DRUG DELIVERY SUMMIT
11:30 - 11:55
EXOSOME-BASED DRUG DELIVERY: OPPORTUNITIES IN ENABLING PERSONALIZED THERAPIES FOR BRAIN DISORDERS
Luís Valente
iLoF

Luís Valente

iLoF

  • Addressing challenges in developing brain-targeted personalized drug therapies
  • Exploring exosomes as natural carriers for CNS-targeted delivery strategies
  • Advancing engineered exosomes for precise delivery in neurological disorders
11:55 - 12:00
Q&A SESSION ON EXOSOMES FOR BRAIN-TARGETED THERAPEUTICS
12:00 - 12:25
EXTENDED-RELEASE AND LONG-ACTING DELIVERY: FROM LIFECYCLE TOOL TO PLATFORM STRATEGY
Edgar A Pogna
L.E.K. Consulting

Edgar A Pogna

L.E.K. Consulting

  • Examining scientific, clinical and commercial drivers accelerating ER and long-acting delivery
  • Balancing adherence gains against CMC, manufacturing and device constraints that erode value
  • Selecting assets for ER development to build a repeatable platform advantage across portfolios
12:25 - 12:30
Q&A SESSION ON EXTENDED-RELEASE AND LONG-ACTING STRATEGY
12:30 - 13:30
NETWORKING LUNCH AND VISITING THE EUROPEAN DRUG DELIVERY SUMMIT
13:30 - 13:55
PROBING LIPID ORDER IN LNPs FOR RNA DELIVERY WITH LAURDAN SPECTROSCOPY
Katharina Beck
Universität Augsburg – Projekt LISO

Katharina Beck

Universität Augsburg – Projekt LISO

  • Investigating lipid structure in RNA LNPs using temperature-sensitive fluorescence dyes
  • Quantifying lipid order with Laurdan to assess nanoparticle stability and membrane density
  • Identifying correlations between lipid order, efficacy, and storage resilience in RNA carriers
13:55 - 14:00
Q&A SESSION ON LNP STRUCTURE, STABILITY AND RNA DELIVERY INSIGHTS
14:00 - 14:25
IMPROVING OUTCOMES THROUGH TARGETED INTERVENTION: MODERN STRATEGIES FOR LOCO-REGIONAL CANCER THERAPY
Helena Kelly
Royal College of Surgeons in Ireland -RCSI

Helena Kelly

Royal College of Surgeons in Ireland -RCSI

  • Advancing catheter, embolic and image-guided systems for high-dose local tumour therapy
  • Integrating formulation factors such as viscosity and release kinetics to improve tumour penetration
  • Exploring device-enabled delivery to overcome tumour barriers and personalise solid tumour care
14:25 - 14:30
Q&A SESSION ON DEVICE-ENABLED LOCO-REGIONAL THERAPY
14:30 - 14:55
ON-BODY INJECTORS & THE 2 ML MYTH: HOW SUBCUTANEOUS VOLUME MISCONCEPTIONS ARE CONSTRAINING DRUG DELIVERY AND DEVELOPMENT
Mehul Desai
Enable Injections, Inc.

Mehul Desai

Enable Injections, Inc.

  • Identifying how subcutaneous volume myths have shaped high-dose development choices
  • Analysing nurse, pharmacist and patient surveys on challenges with large-volume injections
  • Evaluating on-body injectors to ease administration and de-risk delivery development
14:55 - 15:00
Q&A SESSION ON SUBCUTANEOUS ON-BODY INJECTORS
15:00 - 15:30
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:30 - 15:55
VERTICAL HOT MELT EXTRUSION: AN INNOVATIVE APPROACH TO CONTINUOUS MANUFACTURING OF DRUG FORMULATIONS
Mael Gallas
Rondol Group

Mael Gallas

Rondol Group

  • Introducing vertical HME as a compact, scalable alternative to traditional systems
  • Advancing formulation strategies through continuous vertical extrusion platforms
  • Demonstrating pharmaceutical applications for efficient drug manufacturing solutions
15:55 - 16:00
Q&A SESSION ON INNOVATIONS IN CONTINUOUS FORMULATION MANUFACTURING
16:00 - 16:25
UTAC: ENGINEERING A BISPECIFIC THAT CONVERTS CLINICAL ANTIBODIES INTO ORAL FORMULATIONS USING ACTIVE RETRO-TRANSCYTOSIS
Maurits Kleijnen
Intract Pharma Ltd.

Maurits Kleijnen

Intract Pharma Ltd.

  • Designing UTAC bispecifics to ferry clinical antibodies from gut lumen into blood
  • Co-formulating UTAC with clinical IgG to achieve high oral bioavailability in mice
  • Presenting macaque pilot data supporting active retro-transcytosis for oral biologics
16:25 - 16:30
Q&A SESSION ON UTAC-ENABLED ORAL ANTIBODY DELIVERY
16:30 - 16:55
HIGH-RESOLUTION TARGET VALIDATION FOR DRUG DELIVERY USING SPATIAL CELL SORTING
Amos Lee
Meteor Biotech

Amos Lee

Meteor Biotech

  • Enriching rare driver and responder cell states by spatial sorting from intact tissues
  • Generating cell-state multi-omics datasets from selected cells to confirm targets and on-target signatures
  • De-risking translation by turning insights into biomarkers and guidance on required cell reach
16:55 - 17:00
Q&A SESSION ON SPATIAL CELL SORTING FOR VALIDATION
17:00 - 18:00
NETWORKING DRINKS RECEPTION
Day 2 :
THURSDAY, 3 SEPTEMBER, 2026
09:00 - 09:30
MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:05
A NOVEL TARGETED, INTRACELLULAR DELIVERY TECHNOLOGY FOR PROTEIN THERAPEUTICS
Marie McAvoy
NanoSyrinx

Marie McAvoy

NanoSyrinx

  • Introducing nanosyringes for precise intracellular protein therapeutic delivery
  • Unlocking new potential for drugging currently inaccessible intracellular targets
  • Advancing synthetic biology to enable novel modalities for intracellular therapies
10:05 - 10:10
Q&A SESSION ON INTRACELLULAR DELIVERY FOR PROTEIN THERAPEUTICS
10:10 - 10:35
CAVEOLAE PUMPING ACROSS ENDOTHELIUM TO BOOST PRECISION DRUG DELIVERY, POTENCY AND EFFICACY
Jan Schnitzer
Proteogenomics Research Institute for Systems Medicine (PRISM)

Jan Schnitzer

Proteogenomics Research Institute for Systems Medicine (PRISM)

  • Examining endothelial barriers that limit targeting efficiency and heighten systemic toxicity
  • Targeting caveolae to enable precision extravasation of therapeutics across endothelium
  • Enhancing drug concentration and impact through active endothelial transport mechanisms
10:35 - 10:40
Q&A SESSION ON ENDOTHELIAL TARGETING FOR ENHANCED DRUG POTENCY
10:40 - 11:05
FEASIBILITY ASSESSMENTS: PARTNERING EARLY TO MITIGATE COMBINATION PRODUCT DEVELOPMENT RISKS AND IMPROVE SPEED TO
Celine Wassaf
Becton Dickinson (BD)

Celine Wassaf

Becton Dickinson (BD)

  • Identifying key risks in combination product and wearable injector development strategies
  • Demonstrating how early feasibility assessments de-risk device and drug compatibility issues
  • Highlighting case studies on data-driven collaboration to reduce time-to-market obstacles
11:05 - 11:10
Q&A SESSION ON EARLY PARTNERING TO DE-RISK COMBINATION PRODUCTS
11:10 - 11:30
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:30 - 11:55
UNLOCKING THE POTENTIAL OF INTRA-TISSUE DELIVERY FOR ADVANCED THERAPIES, PHARMACEUTICALS AND OTHER THERAPEUTIC PAYLOADS
Ricardo Baptista
SmartCella Holding AB

Ricardo Baptista

SmartCella Holding AB

  • Deploying catheter-based delivery for precise endovascular intra-tissue administration
  • Targeting hard-to-reach tumours, tissues and organs while preserving vascular integrity
  • Enabling repeatable image-guided local dosing with reduced systemic exposure for scale
11:55 - 12:00
Q&A SESSION ON INTRA-TISSUE DELIVERY
12:00 - 12:25
CONNECTED COMBINATION DEVICES FOR RESPIRATORY CARE: SMART INHALERS + AI + IN-SILICO VALIDATION
Nicholas Purcell
Purcell AI

Nicholas Purcell

Purcell AI

  • Quantifying technique and adherence via connected pressure, audio and positioning sensing
  • Linking repeatable airway benchmarks with 3D CFD and PBPK to predict drug deposition
  • Converting real-world signals into app analytics for regulatory and clinical decisions
12:25 - 12:30
Q&A SESSION ON SMART INHALERS AND IN SILICO VALIDATION
12:30 - 12:55
A NEW APPROACH TO NOSE-TO-BRAIN DELIVERY – NOSEPLUG AS A SUSTAINED RELEASE CARRIER IN THE VESTIBULUM
Peter Åhnblad
Hogne AB

Peter Åhnblad

Hogne AB

  • Harnessing mucociliary motion to guide delivery with in-place vestibular device design
  • Stimulating olfactory and trigeminal pathways to enhance brain-targeted uptake efficacy
  • Controlling release kinetics for both immediate and sustained nose-to-brain distribution
12:55 - 13:00
Q&A SESSION ON NASAL DEVICES FOR SUSTAINED BRAIN DELIVERY
13:00 - 13:25
DELIVERING THERAPEUTIC NUCLEIC ACIDS EXTRAHEPATICALLY WITH THE xPHORE PEPTIDE-BASED PLATFORM
Covadonga Paneda
Altamira Therapeutics

Covadonga Paneda

Altamira Therapeutics

  • Clarifying the rationale for peptide carriers to deliver nucleic acids beyond the liver
  • Detailing xPhore flexibility across modalities and targeting options for extrahepatic uptake
  • Showcasing applications in cancer and inflammatory disease with peptide-based delivery designs
13:25 - 13:30
Q&A SESSION ON EXTRAHEPATIC DELIVERY OF NUCLEIC ACIDS
13:30 - 13:45
FEEDBACK & RAFFLE DRAW
13:45 - 15:00
NETWORKING LUNCH

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.